Cerevel Therapeutics Holdings, Inc. announced unaudited consolidated earnings results for the first quarter ended March 31, 2021. For the quarter, the company reported loss from operations of $50,571,000 against $37,702,000 a year ago. Net loss and comprehensive loss was $50,981,000 against $53,208,000 a year ago. Basic and diluted net loss per share was $0.40 against $0.87 a year ago.